research Cutaneous Reactions to Targeted Therapies in Children with CNS Tumors: A Cross-Sectional Study
Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.
Search
for
Did you mean Hand-Foot Skin Reaction?
Sort by
Research
30 / 1000+ results 
research Cutaneous Adverse Events to Systemic Antineoplastic Therapies: A Retrospective Study in a Public Oncologic Hospital
Skin side effects from cancer treatments can lead to changes in therapy and are common, with nail changes being the most frequent.
research Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment
New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
research Sorafenib Stimulates Human Skin Type Mast Cell Degranulation and Maturation
Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.
research Sorafenib-Associated Facial Acneiform Eruption
Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
research Targeted Therapy in Melanoma
New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.
research Cutaneous Toxicities of Cancer Therapy
Cancer therapy can cause various skin problems, including hair loss, skin darkening, painful hand-foot syndrome, and severe skin damage.
research Chemotherapy and Cutaneous Drug Reactions
Chemotherapy can cause skin side effects that affect patients' lives, but they can be managed to avoid interrupting cancer treatment.
research Cutaneous Reactions to Chemotherapeutic Drugs and Targeted Therapy for Cancer
Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
research Skin Toxicity of Anti-Cancer Therapy
Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
research Cutaneous Adverse Effects of BRAF Inhibitors in Metastatic Malignant Melanoma: A Prospective Study in 20 Patients
BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.
research Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.
research Chemotherapy-Induced Iatrogenic Injury of Skin: New Drugs and New Concepts
New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.
research The Incidence and Management of Cutaneous Adverse Events of the Epidermal Growth Factor Receptor Inhibitors
EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.
research Sorafenib Combined with Hepatectomy in Patients with Intermediate-Stage and Advanced Hepatocellular Carcinoma
Sorafenib after liver surgery may increase survival for some liver cancer patients.
research Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
research Supportive Oncodermatology: Addressing Dermatologic Adverse Events Associated with Oncologic Therapies
Cancer survivors often experience worse skin problems from treatment than expected, and working with dermatologists could help improve their condition.
research Prophylaxis and Management of Skin Toxicities
Preventive measures and effective management are crucial for reducing skin side effects in cancer treatment.
research Patient-Level Adverse Event Patterns in a Single-Institution Study of the Multi-Kinase Inhibitor Sorafenib
Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.
research Deferasirox, an Oral Iron Chelator, Prevents Hepatocarcinogenesis and Adverse Effects of Sorafenib
Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
research Cutaneous Drug Reactions
Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.
research Drug Eruptions in Dermatology
Skin reactions to drugs are common and can be deadly, usually requiring stopping the drug and may be better prevented with genetic testing in the future.
research Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
research Clinical Management of Cutaneous Adverse Events in Patients on Targeted Anticancer Therapies and Immunotherapies: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.
research Dermatologic Adverse Events from Cancer Treatments
Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
research The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: The Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.
research A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib
A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.
research Cutaneous Toxicity as a Predictive Biomarker for Clinical Outcome in Patients Receiving Anticancer Therapy
Skin reactions from cancer treatments might predict how well the treatments work.
research Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study
Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.